1. Home
  2. SCLX vs POCI Comparison

SCLX vs POCI Comparison

Compare SCLX & POCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SCLX
  • POCI
  • Stock Information
  • Founded
  • SCLX 2011
  • POCI 1982
  • Country
  • SCLX United States
  • POCI United States
  • Employees
  • SCLX N/A
  • POCI N/A
  • Industry
  • SCLX Biotechnology: Pharmaceutical Preparations
  • POCI Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • Sector
  • SCLX Health Care
  • POCI Health Care
  • Exchange
  • SCLX Nasdaq
  • POCI Nasdaq
  • Market Cap
  • SCLX 35.7M
  • POCI 35.1M
  • IPO Year
  • SCLX N/A
  • POCI N/A
  • Fundamental
  • Price
  • SCLX $13.63
  • POCI $4.71
  • Analyst Decision
  • SCLX Strong Buy
  • POCI
  • Analyst Count
  • SCLX 3
  • POCI 0
  • Target Price
  • SCLX $367.50
  • POCI N/A
  • AVG Volume (30 Days)
  • SCLX 225.6K
  • POCI 5.0K
  • Earning Date
  • SCLX 08-12-2025
  • POCI 05-15-2025
  • Dividend Yield
  • SCLX N/A
  • POCI N/A
  • EPS Growth
  • SCLX N/A
  • POCI N/A
  • EPS
  • SCLX N/A
  • POCI N/A
  • Revenue
  • SCLX $50,710,000.00
  • POCI $17,626,155.00
  • Revenue This Year
  • SCLX $68.30
  • POCI N/A
  • Revenue Next Year
  • SCLX $124.48
  • POCI N/A
  • P/E Ratio
  • SCLX N/A
  • POCI N/A
  • Revenue Growth
  • SCLX 7.79
  • POCI N/A
  • 52 Week Low
  • SCLX $3.60
  • POCI $3.47
  • 52 Week High
  • SCLX $57.75
  • POCI $6.59
  • Technical
  • Relative Strength Index (RSI)
  • SCLX 65.59
  • POCI 46.94
  • Support Level
  • SCLX $10.14
  • POCI $4.63
  • Resistance Level
  • SCLX $17.76
  • POCI $4.89
  • Average True Range (ATR)
  • SCLX 1.79
  • POCI 0.13
  • MACD
  • SCLX 0.52
  • POCI -0.03
  • Stochastic Oscillator
  • SCLX 57.45
  • POCI 21.05

About SCLX Scilex Holding Company

Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.

About POCI Precision Optics Corporation Inc.

Precision Optics Corp Inc is engaged in designing, developing, and manufacturing advanced optical instruments. It manufactures medical products such as endoscopes and endocouplers which incorporate various optical technologies for use in a variety of minimally invasive surgical and diagnostic procedures. The company also produces endoscopes for various applications as well as designs and manufactures custom optical medical devices to satisfy customers' specific requirements. In addition, the company manufactures and sells components and assemblies specially designed for industrial and military use. The company earns the majority of its revenue from the United States.

Share on Social Networks: